 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- B7-H3-targeted GADLEN / Shattuck, CD20 targeting Gamma Delta T cell engager / Shattuck
Antigen targeted butyrophilin heterodimer-based bispecific engagers induce Vγ9δ2+ T cell-mediated anti-tumor activity (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1511;
Similarly, coadministration of GADLEN with Vγ9δ2 + T cells reduced tumor growth in tumor xenografts. Conclusions These results provide proof of concept for in vivo manipulation of γδ T cells using antigen targeted GADLENs for the treatment of hematologic and solid tumor malignancies.